Abstract
Lithium treatment history goes far back before it was thoroughly described in the literature which is now available to us. However, disorders that were initially treated with lithium salts were completely unrelated to psychiatry. The article “Lithium salts in the treatment of psychotic excitement” from 1949 written by John Cade is considered to be the introduction of lithium to modern psychiatric therapy and the beginning of modern clinical psychopharmacology.
In the present treatment guidelines for bipolar disorders lithium is recommended as a first-line maintenance therapy. What is worth mentioning is that the number of indications, including major depressive disorder, for instance, is growing. In addition, numerous meta-analyses focused on antisuicidal effect of lithium therapy were also performed.
On the basis of the most recent literature available in this paper we presented indications for the preventive use of lithium for such disorders as mania, bipolar disorder as well as the occurrence of depressive episodes in major depressive disorder. It is worth pointing out that some studies indicate lithium to be the only medicine proved to be effective for mood stabilization. Interactions between lithium and other medicines were described in detail. In this paper we also described and discussed possible side effects of lithium therapy, including renal failure, hypothyroidism, hyperparathyroidism, weight gain and teratogenicity.
Keywords: Bipolar disorder, depression, lithium, mania, meta-analysis, suicide.
Current Psychopharmacology
Title:Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders
Volume: 3
Author(s): Joanna Iskra-Trifunovic, Mateusz Szymczak, Andrzej Jasiewicz, Anna Grzywacz and Jerzy Samochowiec
Affiliation:
Keywords: Bipolar disorder, depression, lithium, mania, meta-analysis, suicide.
Abstract: Lithium treatment history goes far back before it was thoroughly described in the literature which is now available to us. However, disorders that were initially treated with lithium salts were completely unrelated to psychiatry. The article “Lithium salts in the treatment of psychotic excitement” from 1949 written by John Cade is considered to be the introduction of lithium to modern psychiatric therapy and the beginning of modern clinical psychopharmacology.
In the present treatment guidelines for bipolar disorders lithium is recommended as a first-line maintenance therapy. What is worth mentioning is that the number of indications, including major depressive disorder, for instance, is growing. In addition, numerous meta-analyses focused on antisuicidal effect of lithium therapy were also performed.
On the basis of the most recent literature available in this paper we presented indications for the preventive use of lithium for such disorders as mania, bipolar disorder as well as the occurrence of depressive episodes in major depressive disorder. It is worth pointing out that some studies indicate lithium to be the only medicine proved to be effective for mood stabilization. Interactions between lithium and other medicines were described in detail. In this paper we also described and discussed possible side effects of lithium therapy, including renal failure, hypothyroidism, hyperparathyroidism, weight gain and teratogenicity.
Export Options
About this article
Cite this article as:
Iskra-Trifunovic Joanna, Szymczak Mateusz, Jasiewicz Andrzej, Grzywacz Anna and Samochowiec Jerzy, Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders, Current Psychopharmacology 2014; 3 (1) . https://dx.doi.org/10.2174/2211556003666140319231533
DOI https://dx.doi.org/10.2174/2211556003666140319231533 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lessons Learned from Muscle Fatigue: Implications for Treatment of Patients with Hyperkalemic Periodic Paralysis
Recent Patents on Biotechnology Fragile X Mental Retardation Protein: Many Partners and Multiple Targets for a Promiscuous Function
Current Genomics Localised Delivery of Therapeutic Agents to CNS Malignancies: Old and New Approaches
Current Pharmaceutical Biotechnology FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging Phosphodiesterase 7A: A New Therapeutic Target for Alleviating Chronic Inflammation?
Current Pharmaceutical Design Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Plasma Phospholipids are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients
Current Alzheimer Research The Effects of Creatine Supplementation and Physical Exercise on Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611)
CNS & Neurological Disorders - Drug Targets The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Genetic Studies on the Role of T-Type Ca2+ Channels in Sleep and Absence Epilepsy
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Recent Developments in the Drug Discovery of Epilepsy (Guest Editor: Waquar Ahsan)]
Current Topics in Medicinal Chemistry Development of Polymeric Nanocarriers for Brain Targeted Delivery of Atorvastatin: A Quality-By-Design Approach
Drug Delivery Letters Trigonelline: A Plant Alkaloid with Therapeutic Potential for Diabetes and Central Nervous System Disease
Current Medicinal Chemistry Efficient High-throughput Techniques for the Analysis of Disease- Resistant Plant Varieties and Detection of Food Adulteration
Current Protein & Peptide Science Biodistribution Processes as Underestimated Confounders in Translational Stroke Research
Current Medicinal Chemistry Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Biomedical Applications of Nanomaterials as Therapeutics
Current Medicinal Chemistry